Rapport Therapeutics Prepares for Major Epilepsy Conferences
Rapport Therapeutics, Inc. (Nasdaq: RAPP) is making significant strides in the medical field as it gears up to present at two important epilepsy conferences. This biotechnology company is dedicated to developing innovative treatments for central nervous system (CNS) disorders and aims to highlight its pioneering research and clinical advancements that could reshape the treatment options available for individuals living with epilepsy.
Details on Upcoming Conferences
The first conference is the 15th Annual European Epilepsy Congress (EEC), which will be held in Rome. At this event, Rapport will unveil a novel design for a Phase 2a proof-of-concept trial for its leading product candidate, RAP-219. This cutting-edge approach is designed to assist patients who suffer from drug-resistant focal epilepsy.
The second event, the 2024 Epilepsy Foundation Pipeline Conference, will include an in-depth presentation on the mechanisms behind RAP-219, along with findings from the Phase 2a trial. These presentations underscore Rapport's dedication to enhancing treatment options for complex CNS conditions.
Presentation Highlights
During the EEC, Rapport will present "Novel Design of a Focal Epilepsy Proof-of-Concept Study of RAP-219," emphasizing the significance of their findings. This session is scheduled for Sunday, September 8th, 2024, at 1:30 p.m. CEST and will be led by William Motley, M.D., the Senior Director of Clinical Development.
The Pipeline Conference will also showcase important insights regarding RAP-219. Arnold Gammaitoni, Pharm.D., the Senior Vice President of Medical Affairs, will present on September 26th, detailing how this candidate acts as a powerful negative modulator of the AMPA receptor-associated protein. Each presentation reflects the company's commitment to developing patient-centered treatments for neurological disorders.
About RAP-219 and Rapport Therapeutics
RAP-219 signifies a major breakthrough in the treatment of CNS disorders, utilizing a precision-targeted approach that focuses on specific areas of the brain. This clinical-stage candidate aims not only to manage epilepsy but is also being explored for potential uses in treating peripheral neuropathic pain and bipolar disorder. Rapport Therapeutics is dedicated to pioneering neurological therapies that address the limitations of traditional treatment methods.
Founded on the discovery of receptor associated proteins (RAPs) in the brain, Rapport’s innovative RAP technology platform facilitates the development of targeted solutions that ensure both specificity and efficacy in treatment. The company also boasts a strong pipeline of preclinical and late-stage discovery programs aimed at various CNS-related conditions, including chronic pain and hearing disorders.
Contact Information
For more information or inquiries, please contact Julie DiCarlo, Head of Communications & IR at Rapport Therapeutics, by emailing jdicarlo@rapportrx.com.
Frequently Asked Questions
What is the focus of Rapport Therapeutics?
Rapport Therapeutics is dedicated to discovering and developing small molecule medicines for CNS disorders.
What is RAP-219?
RAP-219 is a clinical trial candidate designed to treat drug-resistant focal epilepsy and other CNS disorders.
When and where will the presentations take place?
The presentations are set for the 15th European Epilepsy Congress in Rome and the 2024 Epilepsy Foundation Pipeline Conference in Atlanta.
Who are the presenters at the conferences?
The presentations will be delivered by William Motley, M.D., and Arnold Gammaitoni, Pharm.D., representing Rapport Therapeutics.
How can I find out more about Rapport's research?
Further details about the presentations and additional information can be accessed on Rapport Therapeutics' website, particularly in the Publications section after the conferences.
